Emerging therapeutics that utilize RNA interference (RNAi) have the potential to treat broad
classes of diseases due to their ability to reversibly silence target genes. In August 2018, the …

The development of biodegradable polymers represents a revolution in medicine spanning
over 50 years and leading to significant biotechnological advancements in drug delivery …

Lipid nanoparticles (LNPs) for the efficient delivery of drugs need to be designed for the
particular administration route and type of drug. Here we report the design of LNPs for the …

In humans, lipid nanoparticles (LNPs) have safely delivered therapeutic RNA to hepatocytes
after systemic administration and to antigen-presenting cells after intramuscular injection …

Polymers represent a promising therapeutic platform for extrahepatic messenger RNA
(mRNA) delivery but are hampered by low in vivo efficacy due to polyplex serum instability …

Nanogels have emerged as a versatile hydrophilic platform for encapsulation of guest
molecules with a capability to respond to external stimuli that can be used for a multitude of …

Polymeric materials have been used in a range of pharmaceutical and biotechnology
products for more than 40 years. These materials have evolved from their earlier use as …

Polymeric micelles (PM) are extensively used to improve the delivery of hydrophobic drugs.
Many different PM have been designed and evaluated over the years, and some of them …

One of the most significant challenges in the development of clinically viable delivery
systems for RNA interference therapeutics is to understand how molecular structures …

The promise of gene therapy for the treatment of cystic fibrosis has yet to be fully clinically
realized despite years of effort toward correcting the underlying genetic defect in the cystic …